Avelox Iv Infusion 400Mg/250Ml (1 Box = 1 Infusion)

Name: Avelox Iv Infusion 400Mg/250Ml (1 Box = 1 Infusion)
Brand: BAYER PHARMA (PVT) LTD.
Price: 1966.5

Brand : bayer pharma (pvt) ltd.

Rs. 1,966.50

Rs. 2,070.00

|

QUICK DELIVERY

Avelox Iv Specification

Requires Prescription (YES/NO)

Yes

Generics

Moxifloxacin HCl

Used For

Bacterial Infection

How it works

Moxifloxacin has in vitro activity against a wide range of Gram-positive and Gram-negative microorganisms. The bactericidal action of moxifloxacin results from inhibition of the topoisomerase II (DNA gyrase) and topoisomerase IV required for bacterial DNA replication, transcription, repair, and recombination. It appears that the C8-methoxy moiety contributes to enhanced activity and lower selection of resistant mutants of Gram-positive bacteria compared to the C8-H moiety. The presence of the bulky bicycloamine substituent at the C 7 position prevents active efflux, associated with the NorA or pmrA genes seen in certain Gram-positive bacteria.

Avelox Iv Usage And Safety

Dosage

Moxifloxacin HCl

Side Effects

BODY AS A WHOLE: Abdominal pain, headache, asthenia, injection site reaction (including phlebitis), malaise, moniliasis, pain, allergic reaction CARDIOVASCULAR: Tachycardia, palpitation, vasodilation, QT interval prolonged DIGESTIVE: Vomiting, abnormal liver function test, dyspepsia, dry mouth, flatulence, oral moniliasis, constipation, GGTP increased, anorexia, stomatitis, glossitis HEMIC AND LYMPHATIC: Leukopenia, eosinophilia, prothrombin decrease (prothrombin time prolonged/International Normalized Ratio (INR) increased), thrombocythemia METABOLIC AND NUTRITIONAL: Lactic dehydrogenase increased, amylase increased MUSCULOSKELETAL: Arthralgia, myalgia NERVOUS SYSTEM: Insomnia, nervousness, vertigo, somnolence, anxiety, tremor SKIN/APPENDAGES: Rash (maculopapular, purpuric, pustular), pruritus, sweating, urticaria SPECIAL SENSES: Taste perversion.

Drug Interactions

Drugs that prolong the QT interval including antiarrhythmics , antipsychotics , neuroleptics , TCADS , antimicrobials , antihistamins , cisapride. Corticosteroids , hypokalaemic agents , anticoagulants, Antacids , didanosine , sucralfate , charcoal , iron or zinc supplements.

Indication

It is indicated for the treatment of adults (> 18 years of age) with infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Acute Bacterial Sinusitis caused by Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis. Acute Bacterial Exacerbation of Chronic Bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, methicillin-susceptible Staphylococcus aureus, or Moraxella catarrhalis.Community Acquired Pneumonia caused by Streptococcus pneumoniae.

When not to Use

Moxifloxacin is contraindicated in persons with a history of hypersensitivity to moxifloxacin or any member of the quinolone class of antimicrobial agents.

Avelox Iv Precautions

Precaution

Quinolones may cause central nervous system (CNS) events, including: nervousness, agitation, insomnia, anxiety, nightmares or paranoia.

Avelox Iv Warnings

Warning 1

Moxifloxacin has been shown to prolong the QT interval of the electrocardiogram in some patients. The drug should be avoided in patients with known prolongation of the QT interval, patients with uncorrected hypokalemia and patients receiving Class IA (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic agents, due to the lack of clinical experience with the drug in these patient populations.

Warning 2

Moxifloxacin should be used with caution in patients with ongoing proarrhythmic conditions, such as clinically significant bradycardia, acute myocardial ischemia. The magnitude of QT prolongation may increase with increasing concentrations of the drug or increasing rates of infusion of the intravenous formulation. Therefore the recommended dose or infusion rate should not be exceeded.

Warning 3

Convulsions have been reported in patients receiving quinolones. Quinolones may also cause central nervous system (CNS) events including: dizziness, confusion, tremors, hallucinations, depression and rarely, suicidal thoughts or acts. These reactions may occur following the first dose. If these reactions occur in patients receiving moxifloxacin, the drug should be discontinued and appropriate measures instituted.

Download the Dvago App